ArticlePloS one2015
Immune Response of Calves Vaccinated with Brucella abortus S19 or RB51 and Revaccinated with RB51.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Recent Advances in Camel Immunology.Frontiers in immunology · 2020Pooled it
- Meta-Analysis of the Changes of Peripheral Blood T Cell Subsets in Patients with Brucellosis.Journal of immunology research · 2018Pooled it
- Brucellosis vaccine development: immunological mechanisms, animal models, and future directions.Archives of microbiology · 2026Review
- Delving into the innate and adaptive immunity of camelids: a paradigm of interspecies adaptation and evolutionary innovation.Frontiers in immunology · 2026Review
- Immunogenicity of a LipopolysaccharideVaccines · 2025Article
- Brucellosis in the omics era: integrative perspectives on Brucella genomic architecture, host-pathogen interactions, and disease dynamics.World journal of microbiology & biotechnology · 2025Review
- Comparison of Long-Term Antibody Titers in Calves Treated with Different Conjunctival and SubcutaneousAnimals : an open access journal from MDPI · 2025Article
- Effect of co-vaccination of cattle with RB51 and BCG on vaccine-specific CD4Frontiers in immunology · 2025Article
- Brucellosis: Unveiling the complexities of a pervasive zoonotic disease and its global impacts.Open veterinary journal · 2024Review
- Parenteral Vaccination with a LiveMicroorganisms · 2024Article
- Immunoinformatic design of a multivalent vaccine againstFrontiers in immunology · 2024Article
- Characterization of the adaptive cellular and humoral immune responses to persistent colonization ofFrontiers in veterinary science · 2024Article
- Article
- A Single Nasal Dose Vaccination with a Brucella abortus Mutant Potently Protects against Pulmonary Infection.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Challenges in Veterinary Vaccine Development.Methods in molecular biology (Clifton, N.J.) · 2022Review
- Activation of mucosal immunity as a novel therapeutic strategy for combating brucellosis.Frontiers in microbiology · 2022Review
- Effect of co-positivity for brucellosis and tuberculosis on milk yield and fertility of Holstein cows.Tropical animal health and production · 2021Article
- Effects of vaccination against brucellosis and clostridia on the intake, performance, feeding behavior, blood parameters, and immune responses of dairy heifers calves.Journal of animal science · 2021Article
- Evaluation of the safety profile of the vaccine candidate Brucella melitensis 16MΔvjbR strain in goats.Vaccine · 2021Article
- Seroprevalence and risk factors for bovine brucellosis in the Chittagong Metropolitan Area of Bangladesh.Veterinary medicine and science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brucella abortus S19 and RB51 strains have been successfully used to control bovine brucellosis worldwide; however, currently, most of our understanding of the protective immune response induced by vaccination comes from studies in mice. The aim of this study was to characterize and compare the immune responses induced in cattle prime-immunized with B. abortus S19 or RB51 and revaccinated with RB51. Female calves, aged 4 to 8 months, were vaccinated with either vaccine S19 (0.6-1.2 x 1011 CFU) or RB51 (1.3 x 1010 CFU) on day 0, and revaccinated with RB51 (1.3 x 1010 CFU) on day 365 of the experiment. Characterization of the immune response was performed using serum and peripheral blood mononuclear cells. Blood samples were collected on days 0, 28, 210, 365, 393 and 575 post-immunization. Results showed that S19 and RB51 vaccination induced an immune response characterized by proliferation of CD4+ and CD8+ T-cells; IFN-ɣ and IL-17A production by CD4+ T-cells; cytotoxic CD8+ T-cells; IL-6 secretion; CD4+ and CD8+ memory cells; antibodies of IgG1 class; and expression of the phenotypes of activation in T-cells. However, the immune response stimulated by S19 compared to RB51 showed higher persistency of IFN-ɣ and CD4+ memory cells, induction of CD21+ memory cells and higher secretion of IL-6. After RB51 revaccination, the immune response was chiefly characterized by increase in IFN-ɣ expression, proliferation of antigen-specific CD4+ and CD8+ T-cells, cytotoxic CD8+ T-cells and decrease of IL-6 production in both groups. Nevertheless, a different polarization of the immune response, CD4+- or CD8+-dominant, was observed after the booster with RB51 for S19 and RB51 prime-vaccinated animals, respectively. Our results indicate that after prime vaccination both vaccine strains induce a strong and complex Th1 immune response, although after RB51 revaccination the differences between immune profiles induced by prime-vaccination become accentuated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.